Eugene Schneider
Chief Tech/Sci/R&D Officer chez IONIS PHARMACEUTICALS, INC.
Fortune : 2 M $ au 31/03/2024
Postes actifs de Eugene Schneider
Sociétés | Poste | Début | Fin |
---|---|---|---|
IONIS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - | - |
Excellus Health Plan, Inc.
Excellus Health Plan, Inc. Managed Health CareHealth Services Excellus Health Plan, Inc. provides health care and long term care insurance plans for individuals and families, sole proprietors, small businesses, and midsize and large businesses in New York. The company is headquartered in New York, NY. | Chief Tech/Sci/R&D Officer | - | - |
Historique de carrière de Eugene Schneider
Anciens postes connus de Eugene Schneider
Sociétés | Poste | Début | Fin |
---|---|---|---|
Biovail Technologies Ltd. | Chief Tech/Sci/R&D Officer | - | - |
SYNAGEVA BIOPHARMA CORP | Chief Tech/Sci/R&D Officer | - | - |
Formation de Eugene Schneider
University of Medicine & Dentistry of New Jersey | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 6 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 4 |
Doctorate Degree | 1 |
Sectorielle
Health Technology | 3 |
Consumer Services | 2 |
Health Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
IONIS PHARMACEUTICALS, INC. | Health Technology |
Entreprise privées | 3 |
---|---|
Excellus Health Plan, Inc.
Excellus Health Plan, Inc. Managed Health CareHealth Services Excellus Health Plan, Inc. provides health care and long term care insurance plans for individuals and families, sole proprietors, small businesses, and midsize and large businesses in New York. The company is headquartered in New York, NY. | Health Services |
Biovail Technologies Ltd. | |
Synageva BioPharma Corp.
Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
- Bourse
- Insiders
- Eugene Schneider
- Expérience